Rongtai health(SH:603579)2020-10-28 16:00Financial Performance - Net profit attributable to shareholders decreased by 23.60% to CNY 159,647,559.79 for the first nine months of the year[6]. - Operating revenue for the first nine months decreased by 13.74% to CNY 1,405,243,697.89 compared to the same period last year[6]. - Basic earnings per share decreased by 22.00% to CNY 1.17[7]. - The weighted average return on equity decreased by 3.29 percentage points to 10.15%[6]. - The company’s net profit after deducting non-recurring gains and losses decreased by 14.72% to CNY 134,255,083.79 for the first nine months[6]. - Net profit for the first three quarters of 2020 was ¥740,089,445.55, a decrease of 8.85% from ¥812,193,428.46 in the same period of 2019[24]. - Net profit for Q3 2020 was ¥58.09 million, compared to ¥71.77 million in Q3 2019, representing a decrease of 19.1%[28]. - The company reported a total comprehensive income of ¥58.04 million for Q3 2020, down from ¥71.84 million in Q3 2019[28]. - Total profit for Q3 2020 was ¥48.52 million, a decrease of 27.7% from ¥67.12 million in Q3 2019[30]. Asset and Liability Changes - Total assets decreased by 9.59% to CNY 2,225,334,849.07 compared to the end of the previous year[6]. - Total assets as of September 30, 2020, amounted to ¥2,294,655,786.42, down from ¥2,454,811,284.74 at the end of 2019[23]. - Total liabilities decreased to ¥718,894,469.32 from ¥806,945,984.73 at the end of 2019, reflecting a reduction of approximately 10.88%[23]. - Shareholders' equity totaled ¥1,575,761,317.10 as of September 30, 2020, down from ¥1,647,865,300.01 at the end of 2019[24]. - The total equity attributable to shareholders was 1,628,991,717.25 RMB, reflecting the company's financial stability[40]. - The company reported a total of 1,734,317,319.01 RMB in current assets, indicating a stable liquidity position[38]. - Current liabilities reached approximately ¥747.91 million, with accounts payable accounting for ¥622.07 million[44]. Cash Flow Analysis - Net cash flow from operating activities decreased by 78.37% to CNY 65,264,870.16 for the first nine months[6]. - Operating cash flow for the first nine months of 2020 was ¥65.26 million, down 78.4% from ¥301.80 million in the same period of 2019[33]. - Total cash inflow from operating activities for the first nine months of 2020 was ¥1.51 billion, a decline of 20.2% from ¥1.89 billion in 2019[33]. - Cash outflow from operating activities totaled ¥1.44 billion, a decrease of 9.0% compared to ¥1.59 billion in the previous year[33]. - The company reported a net decrease in cash and cash equivalents of ¥257.25 million, compared to a decrease of ¥549.24 million in the same period of 2019[34]. - Cash and cash equivalents decreased to ¥618,606,463.28 from ¥875,856,255.08 at the end of 2019[20]. - Cash inflow from financing activities was ¥286.50 million, significantly lower than ¥2.00 million in the previous year[34]. Investment and Expenses - Financial expenses increased significantly by 286.72% to ¥9,036,108, primarily due to fluctuations in the USD exchange rate[12]. - Research and development expenses for Q3 2020 were ¥28,152,371.98, a decrease of 16.06% compared to ¥33,517,170.87 in Q3 2019[26]. - The company incurred credit impairment losses of ¥332,643.23 in Q3 2020, compared to losses of ¥443,842.04 in Q3 2019[30]. - The company has long-term investments totaling 59,004,978.32 RMB, contributing to its asset diversification strategy[38]. - The company has a total of approximately ¥70 million in surplus reserves, enhancing its financial stability[44]. Shareholder Information - The company reported a total of 40,500,400 shares held by the largest shareholder, Lin Qi, representing 28.93% of total shares[10]. - The total number of shareholders at the end of the reporting period was not disclosed[11].